

Deucrava

Deucravacitinib INN

Composition

Deucrava 6 Tablet: Each film coated tablet contains Deucravacitinib INN 6 mg.

Pharmacology

Tyrosine kinase 2 (TYK2) is one of the molecules in human immune system that plays a key role in passing signals throughout the body. This can lead to inflammation and can cause the skin to build up and form plaques. Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of signal transducers and activators of transcription (STATs) as shown in cell-based assays.

Indication

Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Limitations of Use: Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.

Dosage & Administration

Adults (>18 years) recommended dosage is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets.

Use in Pediatric

The safety and effectiveness of Deucravacitinib in pediatric patients have not been established.

Hepatic Impairment

Deucravacitinib is not recommended for use in patients with severe hepatic impairment.

Contraindications

Deucravacitinib is contraindicated in patients with a history of hypersensitivity reactions to deucravacitinib or any of the excipients.

Side Effect

The most common adverse reactions are upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.

Precaution

- Hypersensitivity reactions such as angioedema have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs.
- Avoid use Deucravacitinib in patients with active or serious infection.
- Evaluate for TB prior to initiating treatment with Deucravacitinib.
- Periodically evaluate serum triglycerides. Evaluate liver enzymes of patients with known or suspected liver disease.
- Avoid use Deucravacitinib with live vaccines.

Use in Pregnancy and Lactation

The limited human data on the use of Deucravacitinib in pregnant women are not sufficient to evaluate a drug-associated risk. There are no data on the presence of Deucravacitinib in human milk secretion.

Overdose

There is no experience regarding human overdosage with Deucravacitinib.

Storage

Do not store above 25° C. Protect from light. Keep out of the reach of children.

Packaging

Deucrava 6 Tablet: Each box contains 1x10's tablet in blister pack. Each blister pack is supplied in pouch.

Manufactured by



Ziska Pharmaceuticals Ltd.
Kaliakoir, Gazipur, Bangladesh

Version:00

P-3489